NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 26

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Christian Hospital Northeast 2. 11133 Dunn Road St. Louis, MO 63136	In accordance with application dated May 20, 1985 3. License number 24-13383-01 is amended in its entirety to read as follows:
	4. Expiration date: July 31, 1990
	5. Docket or Reference No.: 030-02382

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 2 curies total for all sources authorized in Subitem 6.E
F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	F. Prepackaged kits	F. 3 millicuries of each byproduct material authorized in Subitem 6.F

1/1 COPY 2

RS 7/17/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 24-13383-01

Docket or Reference number 030-02382

Amendment No. 26

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
G. Xenon-133	G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	G. 2000 millicuries

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

F. *In vitro* studies.

G. Blood flow studies. Pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at Christian Hospital, Northeast, 11133 Dunn Road, St. Louis, Missouri. Licensed material listed in Group I, II, III and VI of 10 CFR 35, Section 35.100, Schedule A may also be used at Christian Hospital Northwest, 1225 Graham Road, Florissant, Missouri.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 24-13383-01

Docket or Reference number 030-02382

Amendment No. 26

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

James Walton Debnam, Jr., M.D.	Groups I, II, III, IV, V and VI Xenon-133 In vitro studies
William L. Walter, M.D.	Strontium-90 medical applicator
Walter G. Holloman, Jr., M.D.	Groups I, II and III Xenon-133 Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction
Donald E. Callahan, M.D.	Groups I, II and IV Xenon-133 In vitro studies
Fred R. Zivnuska, M.D.	Group VI
Fransiska A. Lee, M.D.	Group VI
Robert J. Baglan, M.D.	Group VI
Lily A. Hanes, M.D.	Group VI
Karen F. Goodhope, M.D.	Groups I, II and III Xenon-133 In vitro studies Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

(a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

(b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 24-13383-01

Docket or Reference number 030-02382

Amendment No. 26

(c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

15. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

16. The licensee shall establish a bioassay program for individuals handling millicurie amounts of iodine-131 in accordance with frequencies and procedures contained in Regulatory Guide 8.20, "Applications of Bioassay for I-125 and I-131."

17. Pursuant to Section 20.105(a) of Title 10, Chapter 1, Code of Federal Regulations, Part 20, "Standards for Protection Against Radiation," and in reliance of statements, procedures and representations made by the licensee in his application dated November 14, 1983, letters dated February 22, 1984, and May 20, 1985 (with attchments), the following maximum radiation levels are hereby authorized in the following unrestricted areas:

Maximum Radaition Level	Unrestricted Area
5mR/hour	Areas adjacent to Room 326 Christian Hospital Northwest

18. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated July 23, 1979 and November 14, 1983; letter with attached application dated May 20, 1985; letters dated February 22, 1984, October 11, 1984, and February 5, 1985; and the Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed
By J.R. Madera
Materials Licensing Section, Region III

Date July 17, 1985

COPY